Clinical trials: Secondary Arthritis
Osteoarthritis Of Knee
Geniculate Artery Embolization for the Treatment of Knee Pain
This study is to test a new treatment method, geniculate artery embolization (GAE), to reduce the severity of pain and disability caused by knee osteoarthritis.
- Trial name
- GAE (NCT02850068)
- Testing
- Geniculate Artery Embolization
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Early Rheumatoid Arthritis
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
The purpose of the study is to assess the safety and efficacy of adalimumab in combination with methotrexate in patients with recent onset rheumatoid arthritis (RA), and to assess the long-term safety and maintenance of efficacy…
- Trial name
- PREMIER (NCT00195663)
- Testing
- Adalimumab, Methotrexate
- Where
- 123 sites in United States, Australia and 17 more
- Volunteers
- 799 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Gout
Gout Self-Monitoring Aiming to Reach Target
This study evaluates whether a supported self-management approach to gout is able to achieve target levels of serum urate, and better control of gout flares.
- Trial name
- Gout-SMART (NCT03274063)
- Testing
- Supported self-management, Usual care
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Edinburgh
Inflammatory Tissue Disorder, Osteoarthritis
Mobile - Bearing Knee Study
To evaluate the safety and efficacy of the Encore Mobile-Bearing Knee.
- Conditions
- Inflammatory Tissue Disorder, Osteoarthritis, Avascular Necrosis, Post-traumatic Arthritis
- Trial name
- NCT00765362
- Testing
- Encore Mobile-Bearing Knee
- Where
- 8 sites in United States
- Volunteers
- 419 people
- Sponsor
- Encore Medical, L.P.
Rheumatoid Arthritis
Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia
Purpose of the study is to determine if Cimzia is safe and effective in subjects who have received previous treatment with a TNF-alpha inhibitor other than Cimzia.
- Trial name
- NCT01147341
- Testing
- Cimzia
- Where
- 12 sites in United States
- Volunteers
- 37 people
- Sponsor
- Michael Schiff, MD
Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic
A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset…
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Trial name
- NCT03311854
- Testing
- Emapalumab
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- Swedish Orphan Biovitrum
Osteo Arthritis Knee
Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)
Purpose: To evaluate embolization as a treatment for OA related knee pain versus placebo to demonstrate the actual effect of embolization on pain and disability.
- Trial name
- NCT03362957
- Testing
- Geniculate Artery Embolization
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of North Carolina, Chapel Hill
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum